Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of DWP213388 in Healthy Adults
NCT05607589Phase 1Withdrawn
- Sponsor
- Daewoong Pharmaceutical
- Start
- Oct 2022
- Primary completion
- Feb 2024
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial in autoimmune diseases comparing DWP213388 with Placebo (2 arms). Primary endpoints: Treatment-Emergent Adverse Events and 12-lead Electrocardiogram. Planned start Oct 2022; status: withdrawn.
02
Drugs
dwp213388
03
Conditions
autoimmune diseases
Beyond the preview
Go deeper on NCT05607589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05607589.